Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Company Shares of NxStage Medical, Inc. Rally 1.68% - American Trade Journal |
 |
 |
|
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) appreciated by 1.68% during the past week but lost 6.88% on a 4-week basis. The shares have outperformed the S&P 500 by 1.69% in the past week but underperformed the index by 6.09% in the last 4 weeks. For the current week, the company shares have a recommendation consensus of Buy. Nxstage Medical, Inc. has dropped 22.14% during the last 3-month period . Year-to-Date the stock performance stands at -19.19%. The company shares have rallied 6.15% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $15.36 and the 200 day moving average is recorded at $17.18. S&P 500 has rallied 5.03% during the last 52-weeks. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $14.24 and hit $14.56 on the upside , eventually ending the session at $14.49, with a gain of 2.48% or 0.35 points. The heightened volatility saw the trading volume jump to 380,210 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $916 million. The 52-week low of the share price is at $11.5 . On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The (President), of Nxstage Medical, Inc., Turk Joseph E Jr had unloaded 2,000 shares at $15.36 per share in a transaction on June 23, 2015. The total value of transaction was $30,720. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
